Inhibikase Therapeutics, Inc. Shares Issued, Shares, Share-based Payment Arrangement, Forfeited
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Inhibikase Therapeutics, Inc. shares issued, shares, share-based payment arrangement, forfeited for the quarter ending 2026-06-30 was 0.00 shares.
- Inhibikase Therapeutics, Inc. shares issued, shares, share-based payment arrangement, forfeited for the quarter ending 2026-03-31 was 1.66M shares.
| Period end | Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 3 month | Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | |
| 2026-03-31 | 1.66M shares 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |